Abstract 4369397: <u>Uncovering the Role of T-Cell and Fibroblast Crosstalk in Immunotherapy-Induced Myocarditis</u>

N Noah Wagner (Stanford Cardiovascular Institute, San Carlos, California, United States) M Maria Rosaria Vitale (Stanford School of Medicine, Palo Alto, California, United States) Y Yin Sun (Department of Chemistry, Graduate School of Science, The University of Tokyo) M Maria Zambrano (Tufts University, Boston, Massachusetts, United States) A Abraham Bayer (Tufts University, Boston, Massachusetts, United States) P Pilar Alcaide J Javid Moslehi (Section of Cardio-Oncology and Immunology Section, Department of Medicine, University of California San Francisco (J.M.).) H Han Zhu (State Key Laboratory of Medicinal Chemical Biology, Frontiers Science Centre for New Organic Matter, Tianjin Key Laboratory of Biosensing and Molecular Recognition, Research Centre for Analytical Sciences, College of Chemistry, School of Medicine, and Frontiers Science Centre for Cell Responses)

Abstract

Introduction: Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that activate immune cells against tumor cells but can cause immune related adverse events such as myocarditis, a serious side effect with up to 40% case fatality rate. We hypothesize that cardiac fibroblasts and cytotoxic T-Cells work in tandem to direct inflammation in the setting of ICI treatment, resulting in myocarditis. Methods: To study the role of CFBs in ICIM, we first examined fibroblast behavior in vivo through picrosirius red staining for cardiac fibrosis. We then cultured C57BL/6 murine CFBs and treated them with cardiac serum acquired from a genetic mouse model of ICIM and analyzed Cxcl9 expression by qPCR. Additionally, we stimulated CFBs with media or IFNγ for 24 hours (uCFBs and sCFBs respectively) before co-culturing them with CD8 CXCR3hi T-Cells for 6 hours, after which we analyzed Cxcl9 and Cxcl10 CFB expression by qPCR (Fig 1C) and T-Cell cytotoxicity by flow cytometry (Fig 1D/E). We next examined CD8 T-Cells harvested from C57BL/6 mice treated with combination immunotherapy to induce ICIM via single-cell sequencing to investigate potential axes of T-Cell/CFB crosstalk in vivo . Results: Our picrosirius red staining revealed a significant increase in cardiac interstitial and perivascular fibrosis, suggesting that CFBs are inflammatorily active and fibrotic in the context of ICIM (Fig 1A). We demonstrated that treating CFBs with ICIM cardiac serum results in a significant upregulation of CXCL9 by qPCR (Fig 1B). Utilizing our co-culture system, we demonstrated that the presence of CD8 CXCR3hi cytotoxic T-cells significantly increases CXCL9/10 expression compared to both control and IFNγ stimulation, underscoring the importance of T-cell presence in CFB activation (Fig 1C). We also used flow cytometry to confirm the cytotoxic quality of the T-Cells used in our co-culture system (Fig 1D/E). Using single-cell sequencing, we identified a cluster of CXCR3hiVLA4hi CD8 T-Cells from ICI-treated myocarditis mice (Fig 1F.) which are highly cytotoxic compared to other clusters (Fig 1G.), demonstrating that VLA-4:VCAM-1 signaling between T-cells and CFBs may act as a critical driver of cytotoxicity in the heart. Conclusions: Our findings position cardiac fibroblasts as potentially critical drivers of T-Cell migration and increased cytotoxicity in the context of ICIM, rendering this crosstalk an important direction of study in future of understanding and treating ICIM.

Article Details

Journal Circulation
Volume / Issue Vol. 152, Issue Suppl_3
Published November 04, 2025
ISSN 0009-7322
Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (8)

N

Noah Wagner

Stanford Cardiovascular Institute, San Carlos, California, United States

M

Maria Rosaria Vitale

Stanford School of Medicine, Palo Alto, California, United States

Y

Yin Sun

Department of Chemistry, Graduate School of Science, The University of Tokyo

M

Maria Zambrano

Tufts University, Boston, Massachusetts, United States

A

Abraham Bayer

Tufts University, Boston, Massachusetts, United States

P

Pilar Alcaide

J

Javid Moslehi

Section of Cardio-Oncology and Immunology Section, Department of Medicine, University of California San Francisco (J.M.).

H

Han Zhu

State Key Laboratory of Medicinal Chemical Biology, Frontiers Science Centre for New Organic Matter, Tianjin Key Laboratory of Biosensing and Molecular Recognition, Research Centre for Analytical Sciences, College of Chemistry, School of Medicine, and Frontiers Science Centre for Cell Responses